Prostate Cancer News and Research

Latest Prostate Cancer News and Research

PROTAC technology offers hope for treating castration-resistant prostate cancer

Announcing a new publication for Acta Materia Medica journal. Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men.

30 Jan 2025

Climate change is pushing up rates of kidney disease and urological cancers

Climate change is increasing the risk of urological diseases, including cancer and kidney conditions, while urological healthcare itself contributes to environmental harm through high carbon emissions.

29 Jan 2025

New urine test shows promise for prostate cancer screening

Traditional approaches to prostate cancer screening involve blood tests, MRI, and biopsies.

28 Jan 2025

Inherited gene mutation found to increase prostate cancer risk

A study of men with a family history of prostate cancer has discovered an inherited form of prostate cancer.

28 Jan 2025

Developmental epigenetic changes could shape cancer risk later in life

A person's lifetime risk for cancer may begin before they are even born, reports a paradigm-shifting study by Van Andel Institute scientists.

27 Jan 2025

Study highlights potential of genomic tests for early stage prostate cancer

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests - Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris - can help doctors make better decisions about how to treat patients with early stage prostate cancer.

24 Jan 2025

OncoAssure announces clinical validation of prostate cancer test

OncoAssure Ltd, an Irish medical diagnostic company, today announced the publication of new data, in the British Journal of Urology International Compass (BJUI Compass), which demonstrates the clinical validation of OncoAssure Prostate, a novel biopsy test which provides improved estimation of a patient’s risk of prostate cancer recurrence and allows for optimal treatment selection.

21 Jan 2025

Expert consensus provides unified framework for prostate cancer care in China

While prostate cancer is becoming more prevalent among middle-aged and elderly men in China, clinical practice still faces considerable challenges due to the lack of unified guidelines and high-level evidence on several aspects of patient care.

20 Jan 2025

Exploring the use of genomic classifier tests in prostate cancer risk stratification

A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for better data on their cost-effectiveness, clinical utility, and their impact on racial and ethnic groups, particularly Black men.

20 Jan 2025

New resource from NCCN offers guidance on hereditary cancer risk

Today, the National Comprehensive Cancer Network (NCCN)-an alliance of leading cancer centers-published a new resource to inform people about the latest recommendations around hereditary and familial cancer risk.

16 Jan 2025

NCCN global meeting focuses on cancer care in the MENA region

The National Comprehensive Cancer Network (NCCN)-a global not-for-profit alliance of leading cancer centers-is taking part in a two-day meeting at the Middle East North Africa (MENA)-NCCN Regional Coordinating Center, beginning today.

11 Jan 2025

Machine learning reveals why cancer trials fall short in real-world patients

TrialTranslator uses machine learning to assess cancer RCT generalizability, revealing survival gaps for high-risk patients and enhancing research accuracy.

10 Jan 2025

RNA nanoparticles offer dual action against prostate tumors

Yang Zhang, PhD, and Jinjun Shi, PhD, both of the Center for Nanomedicine and Department of Anesthesiology, Perioperative and Pain Medicine at Brigham and Women's Hospital, are co-senior authors of a paper published in ACS Nanoscience Au, "Lipid Nanoparticle Delivery of mRNA and siRNA for Concurrent Restoration of Tumor Suppressor and Inhibition of Tumorigenic Driver in Prostate Cancer."

10 Jan 2025

Functional characterization of variants improves cancer risk assessment and treatment

Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center have significantly advanced the understanding of genetic alterations in the BRCA2 gene, a key player in hereditary cancer risk.

9 Jan 2025

New AI system aims to improve real-world application of clinical trial results

A new study led by Winship Cancer Institute of Emory University and Abramson Cancer Center of University of Pennsylvania researchers demonstrates that a first-of-its-kind platform using artificial intelligence (AI) could help clinicians and patients assess whether and how much an individual patient may benefit from a particular therapy being tested in a clinical trial.

8 Jan 2025

Researchers explore steam treatment for prostate cancer

Steam eliminates wrinkles and germs, but can it destroy cancer cells too?

7 Jan 2025

Advanced imaging technology detects undiagnosed metastases in high-risk prostate cancer

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than previously thought.

3 Jan 2025

Patient-centered reports help reduce worry and improve understanding of test results

In April 2021, a provision in the 21st Century Cures act took effect which required that all medical test results be released to a patient's electronic medical record as soon as they become available.

3 Jan 2025

LGBTQ+ people relive old traumas as they age on their own

Bill Hall, 71, has been fighting for his life for 38 years. These days, he's feeling worn out.

24 Dec 2024

Assessing the impact of gozetotide in PSMA-positive prostate cancer

Gozetotide is a drug for diagnostic application in adults with prostate cancer. It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify patients for whom PSMA-targeted therapy with (177Lu)lutetium vipivotide tetraxetan ("Lutetium-177" for short) is an option.

20 Dec 2024